Allogene Therapeutics, Inc. revenue

Allogene Therapeutics, Inc.'s revenue was $0 in fiscal 2025, down 100.0% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Allogene Therapeutics, Inc.: revenue history, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	114	0	0	0	0
Growth on the year before	—	—	—	−99.9%	−39.1%	−76.8%	−100.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Allogene Therapeutics, Inc.: revenue history, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Revenue	0	0	0	0	0	0	0	4,640

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allogene Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allogene Therapeutics, Inc.